InCarda Therapeutics
Exhibitions · Hospitals & Health Systems
$63.3Mtotal raised · 3 rounds on record
$28Mlatest round · Venture round · Oct 2020 · 6 yr ago
2backers · HealthCap, Sofinnova Investments
50+team · employees, estimated range
Overview
Developing novel treatments for patients with atrial fibrillation. We are developing drugs designed to safety, effectively, and quickly get patients back to where they belong - in normal sinus rhythm.
Funding and backers
Total raised
$63.3M
3 rounds on record
Latest round
$28M
Venture round · Oct 2020 · 6 yr ago
Team
51-200
employees, estimated range
Backers
2
HealthCap, Sofinnova Investments
The money's age
Long since its last round
73 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 6, 2020
Raised a round Venture round $28M · SEC Form D
Oct 20, 2017
Raised a round Venture round $35.3M · SEC Form D
Mar 9, 2017
Took on debt financing $2.1M · SEC Form D
Nov 2011
Website went live first capture in the Wayback Machine
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2020 | $28M | — | SEC Form D |
| Venture round | Oct 2017 | $35.3M | — | SEC Form D |
| Debt Financing | Mar 2017 | $2.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | InCarda Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Rangachari NarasimhanExecutive Officer, DirectorSEC Form D
Grace ColonExecutive Officer, DirectorSEC Form D
Miller SamanthaExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs S4 Medical -
Similar startupsby what they do, their industry and backers
Kintsugi is developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free form speech…
Redefining Care. Advancing COPD and Other Respiratory Therapies. Expedition Therapeutics is developing novel treatments for inflammatory…
Maxwell Biomedical is developing Cardiomodulation, a non-destructive electrical therapy for atrial fibrillation designed to preserve atrial…
Our people take the time to get to know you, your family, and your business. Get to know us and you’ll see that you belong at Union Bank &…
Online chronic pain recovery program designed to get you back to the life you want to live. One-on-one coaching. Real pain reduction…
Inomagen Therapeutics. Developing a non-viral disease-modifying gene therapy to improve the treatment of atrial fibrillation.
People
Rangachari Narasimhan
Executive Officer, Director
Grace Colon
Executive Officer, Director
Miller Samantha
Executive Officer
McCarthy Reenie
Director
Bischofberger Norbert
Director
Isaac Cheng
Director
Alan Colowick
Director
Johan Christenson
Director
Andrew ElBardissi
Director
Dan Welch
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
HealthCapVia a fund
Sofinnova InvestmentsVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Newark
United States
HQ
50-200 est. staff